Navigation Links
AACR, NCI and EORTC to host Molecular Targets and Cancer Therapeutics International Conference
Date:11/9/2009

PHILADELPHIA Scientists and industry leaders from around the world will gather in Boston Nov. 14-19, 2009, for the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference, which will feature groundbreaking information on important cancer therapies in development.

"Cancer is a complex disease and to treat it effectively we need a greater understanding of the activity that takes place at the molecular level," said Lewis Cantley, Ph.D., director of the cancer center at Beth Israel Deaconess Medical Center and one of the scientific committee chairpersons of the conference. "The research presented at this conference will bring us closer to that understanding."

Experts from the world's leading cancer centers and pharmaceutical companies will discuss innovations in drug development, target selection and the impact of new discoveries in molecular and cellular biology.

Understanding the pathways and mechanisms that cause cancer and regulate the biological behavior of tumor cells has already led to the development of numerous new agents. This conference, now in its second decade, has been organized to reflect the many recent advances in the early development of promising new compounds.

During the conference, the American Association for Cancer Research will host several press briefings: "Drugs in the Pipeline," "Emerging Therapies in Pancreatic Cancer" and "Markers of Prognosis."


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related biology news :

1. AACR, NCI and EORTC to host molecular targets and cancer therapeutics conference
2. AACR, BCRF award inaugural grants in translational breast cancer research
3. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
4. Trembling hands and molecular handshakes
5. NHLBI awards $11 million for molecular roadmap to chronic lung diseases
6. Cements basic molecular structure finally decoded
7. Powerful new molecular GPS helps probe aging and disease processes
8. Think zinc: Molecular sensor could reveal zincs role in diseases
9. Stimulus funding helps K-State bring undergrads to prairie for ecology, molecular biology research
10. Pitt study finds molecular link between insulin resistance and inflammation
11. Stem cell research: From molecular physiology to therapeutic applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology: